<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716885</url>
  </required_header>
  <id_info>
    <org_study_id>1781</org_study_id>
    <nct_id>NCT00716885</nct_id>
  </id_info>
  <brief_title>The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing</brief_title>
  <acronym>OXIS-PACING</acronym>
  <official_title>The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess whether a correlation exist between the degree of pulmonary clearance of free
           radical positive white bloodcells and platelets and the degree of pulmonary congestion
           in congestive heart failure (CHF) patients

        2. To asses whether cardiac resynchronization therapy improves pulmonary clearance of free
           radical positive white blood cells and platelets in CHF patients by alleviating
           pulmonary congestion

        3. Interaction of oxidative stress with circulating endothelial progenitor cells (EPCs) and
           presence of apoptotic endothelial (progenitor) cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence exists that oxidative stress is enhanced in congestive heart failure patients
      resulting in damage to cellular lipids, proteins and DNA. Because of free radical-induced
      apoptosis of skeletal muscle fibers, oxidative stress is an important contributor to skeletal
      muscle fatigue and low exercise tolerance of congestive heart failure patients. Enhanced
      oxidative stress in congestive heart failure can exert negative inotropic effects and can
      have important effects on the structure and function of the myocardium, and may be implicated
      in the progression of congestive heart failure. Free radical stress could also impair
      recruitment and differentiation of circulating endothelial progenitor cells resulting in
      increased all cause mortality.

      Reduced pulmonary clearance of free radical loaded white blood cells and platelets is an
      important contributor to enhanced oxidative stress in congestive heart failure patients.
      Failure of pulmonary clearance of free radical loaded white blood cells and platelets
      probably results from pulmonary congestion which has led to the rationale of the current
      study. Biventricular pacing for resynchronization therapy in congestive heart failure
      patients reduces left ventricular filling pressure and pulmonary congestion. Biventricular
      pacing may therefore augment pulmonary clearance of free radical loaded white blood cells and
      platelets in congestive heart failure patients.

      We conduct a prospective, observational clinical study to investigate the correlation of left
      ventricular filling pressure, pulmonary clearance of FR loaded circulating white blood cells
      and platelets and number of endothelial progenitor cells in congestive heart failure (CHF)
      patients before and after implantation of a biventricular pacemaker for resynchronization
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>• Number of (apoptotic) endothelial (progenitor) cells</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Oxidative stress: cytosolic and mitochondrial FR</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>CHF</arm_group_label>
    <description>Informed consented participants are recruited among all patients admitted to the OLVG hospital.
Inclusion criteria:
Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy
Dyspnoe NYHA class III and IV
Optimal and constant heart failure treatment according to the ESC guidelines
Exclusion criteria:
Renal failure (creatinine &gt;1.70 mg/dl)
Signs of infection or inflammation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bloodsamples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the OLVG hospital for worsening congestive heart failure selected for
        biventricular pacemaker implantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient selection

        Informed consented participants are recruited among all patients admitted to the OLVG
        hospital.

        Inclusion criteria:

          -  Chronic congestive heart failure patients of all ages selected for biventricular
             pacemaker implantation for resynchronization therapy

          -  Dyspnoe NYHA class III and IV

          -  Optimal and constant heart failure treatment according to the ESC guidelines

        Exclusion criteria:

          -  Renal failure (creatinine &gt; 1.70 mg/dl)

          -  Signs of infection or inflammation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Walter J Paulus, Professor</last_name>
    <phone>00 31 20 444 8110</phone>
    <email>wj.paulus@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander J IJsselmuiden, MD, PhD</last_name>
    <phone>00 31 20 444 8110</phone>
    <email>ijsselmuiden@vumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLVG Hospital</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1090hm</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>G. A. Somsen, MD,PhD</last_name>
      <phone>+31 (0) 20 5993032</phone>
      <email>g.a.somsen@olvg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.vcmo.nl</url>
    <description>United Committee Human Research (the Netherlands)</description>
  </link>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>July 14, 2008</last_update_submitted>
  <last_update_submitted_qc>July 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Professor dr. Walter J. Paulus</name_title>
    <organization>VU University Medical Center</organization>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Endothelial Progenitor Cells</keyword>
  <keyword>White blood cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

